- A prospective multicenter study reported:
- A significant improvement in:
- Overall and disease-specific mortality, as well as disease-free survival:
- In National Thyroid Cancer Cooperative Study Group (NTCTCSG):
- Stage III and IV patients:
- After statistical adjustment using multivariable and propensity stratified analyses
- Stage III and IV patients:
- In National Thyroid Cancer Cooperative Study Group (NTCTCSG):
- Overall and disease-specific mortality, as well as disease-free survival:
- A significant improvement in:
- Furthermore, prospectively collected data from the SEER cancer registry:
- Suggest that postsurgical RAI therapy is associated with improved overall survival:
- In patients with PTC with distant metastases:
- When distant metastases were combined with:
- Age greater than 45 years
- Tumor size greater than 2 cm
- Positive lymph nodes at primary diagnosis
- When distant metastases were combined with:
- In patients with PTC with distant metastases:
- Data from the SEER database also suggest that overall survival:
- In patients with FTC with distant metastases:
- More than doubled in patients receiving postsurgical RAI treatment
- In patients with FTC with distant metastases:
- Suggest that postsurgical RAI therapy is associated with improved overall survival:
- Thus:
- Routine postsurgical RAI treatment is re- commended in patients with ATA high-risk DTC

#Arrangoiz #CancerSurgeon #ThyroidSurgeon #ThyroidExpert #HeadandNeckSurgeon #RAI #ThryoidCancerTreatment #CASO #CenterforAdvancedSurgicalOncology